These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 38672492)

  • 41. Dietary and pharmacological treatment in patients with metabolic-dysfunction associated steatotic liver disease.
    Armandi A; Bugianesi E
    Eur J Intern Med; 2024 Apr; 122():20-27. PubMed ID: 38262842
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Roles of Activin A and Gpnmb in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Liu H; Yerevanian A; Westerhoff M; Hastings MH; Guerra JRB; Zhao M; Svensson KJ; Cai B; Soukas AA; Rosenzweig A
    Diabetes; 2024 Feb; 73(2):260-279. PubMed ID: 37934943
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Natural history of metabolic dysfunction-associated steatotic liver disease.
    Lekakis V; Papatheodoridis GV
    Eur J Intern Med; 2024 Apr; 122():3-10. PubMed ID: 37940495
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lipid Metabolism in Metabolic-Associated Steatotic Liver Disease (MASLD).
    Syed-Abdul MM
    Metabolites; 2023 Dec; 14(1):. PubMed ID: 38248815
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Genetic Ablation of STE20-Type Kinase MST4 Does Not Alleviate Diet-Induced MASLD Susceptibility in Mice.
    Caputo M; Andersson E; Xia Y; Hou W; Cansby E; Erikson M; Lind DE; Hallberg B; Amrutkar M; Mahlapuu M
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397122
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of Wild-Type and High-risk PNPLA3 variants in a Human Biomimetic Liver Microphysiology System for Metabolic Dysfunction-associated Steatotic Liver Disease Precision Therapy.
    Xia M; Varmazyad M; Palacin IP; Gavlock DC; Debiasio R; LaRocca G; Reese C; Florentino R; Faccioli LAP; Brown JA; Vernetti LA; Schurdak ME; Stern AM; Gough A; Behari J; Soto-Gutierrez A; Taylor DL; Miedel M
    bioRxiv; 2024 May; ():. PubMed ID: 38712213
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Saturated Fat-Mediated Upregulation of IL-32 and CCL20 in Hepatocytes Contributes to Higher Expression of These Fibrosis-Driving Molecules in MASLD.
    Schilcher K; Dayoub R; Kubitza M; Riepl J; Klein K; Buechler C; Melter M; Weiss TS
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686029
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Surfactant protein A promotes western diet-induced hepatic steatosis and fibrosis in mice.
    Dare A; King SD; Chen SY
    Sci Rep; 2024 Mar; 14(1):7464. PubMed ID: 38553537
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Gut microbiota-derived indole compounds attenuate metabolic dysfunction-associated steatotic liver disease by improving fat metabolism and inflammation.
    Min BH; Devi S; Kwon GH; Gupta H; Jeong JJ; Sharma SP; Won SM; Oh KK; Yoon SJ; Park HJ; Eom JA; Jeong MK; Hyun JY; Stalin N; Park TS; Choi J; Lee DY; Han SH; Kim DJ; Suk KT
    Gut Microbes; 2024; 16(1):2307568. PubMed ID: 38299316
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Metabolic Dysfunction-Associated Steatotic Liver Disease in a Dish: Human Precision-Cut Liver Slices as a Platform for Drug Screening and Interventions.
    Li M; Larsen FT; van den Heuvel MC; Gier K; Gorter AR; Oosterhuis D; Bijzet J; de Meijer VE; Ravnskjaer K; Nagelkerke A; Olinga P
    Nutrients; 2024 Feb; 16(5):. PubMed ID: 38474754
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: Nationwide multigenerational cohort study.
    Ebrahimi F; Hagström H; Sun J; Bergman D; Shang Y; Yang W; Roelstraete B; Ludvigsson JF
    J Hepatol; 2023 Dec; 79(6):1374-1384. PubMed ID: 37647992
    [TBL] [Abstract][Full Text] [Related]  

  • 52. NLRP3 Inflammasome: A Possible Link Between Obesity-Associated Low-Grade Chronic Inflammation and Colorectal Cancer Development.
    Ahechu P; Zozaya G; Martí P; Hernández-Lizoáin JL; Baixauli J; Unamuno X; Frühbeck G; Catalán V
    Front Immunol; 2018; 9():2918. PubMed ID: 30619282
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma.
    Wang Y; Fleishman JS; Li T; Li Y; Ren Z; Chen J; Ding M
    Front Pharmacol; 2023; 14():1336216. PubMed ID: 38313077
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Can Nutraceuticals Support the Treatment of MASLD/MASH, and thus Affect the Process of Liver Fibrosis?
    Sokal-Dembowska A; Jarmakiewicz-Czaja S; Ferenc K; Filip R
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791276
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adapted Immune Responses of Myeloid-Derived Cells in Fatty Liver Disease.
    Hundertmark J; Krenkel O; Tacke F
    Front Immunol; 2018; 9():2418. PubMed ID: 30405618
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Incretin-based investigational therapies for the treatment of MASLD/MASH.
    Brouwers B; Rao G; Tang Y; Rodríguez Á; Glass LC; Hartman ML
    Diabetes Res Clin Pract; 2024 May; 211():111675. PubMed ID: 38636848
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study.
    Kouvari M; Valenzuela-Vallejo L; Guatibonza-Garcia V; Polyzos SA; Deng Y; Kokkorakis M; Agraz M; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; George J; Mingrone G; Mantzoros CS
    Metabolism; 2023 Oct; 147():155666. PubMed ID: 37527759
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Myosteatosis: Diagnosis, pathophysiology and consequences in metabolic dysfunction-associated steatotic liver disease.
    Henin G; Loumaye A; Leclercq IA; Lanthier N
    JHEP Rep; 2024 Feb; 6(2):100963. PubMed ID: 38322420
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Role of inflammasomes and cytokines in immune dysfunction of liver cirrhosis.
    Pratim Das P; Medhi S
    Cytokine; 2023 Oct; 170():156347. PubMed ID: 37639845
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: A community-dwelling cohort study with 20-year follow-up.
    Choe HJ; Moon JH; Kim W; Koo BK; Cho NH
    Metabolism; 2024 Apr; 153():155800. PubMed ID: 38266957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.